MENLO PARK, Calif. & NEWTON, Mass.–(BUSINESS WIRE)–Estuary Biotherapeutics, Inc., a biotechnology company developing genetic medicines for patients with serious kidney diseases, today announced its launch with $103 million in total committed financing. The $93 million Series A was led by RA Capital Management and included participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund and a family office
